The progress against pancreatic cancer
Pancreatic cancer, long considered a death sentence, is becoming more treatable thanks to new therapies like daraxonrasib, which has shown significant tumor reduction and doubled survival in metastatic cases. The drug targets the previously 'undruggable' RAS protein and is part of a new class of treatments called molecular glues. These advances mark a turning point not only for pancreatic cancer but for oncology more broadly.
- ▪Former Nebraska Senator Ben Sasse experienced a 76 percent reduction in tumor volume after enrolling in a clinical trial for daraxonrasib.
- ▪In April 2026, Phase 3 trial results showed daraxonrasib roughly doubled survival in metastatic pancreatic cancer patients compared to standard chemotherapy.
- ▪Daraxonrasib is among the first drugs to successfully target mutant RAS proteins, implicated in about 25 percent of all human cancers.
- ▪Pancreatic cancer is often diagnosed late due to its deep location and vague symptoms, earning it the nickname 'silent killer'.
- ▪Immunotherapies like checkpoint inhibitors and CAR-T have had limited success in pancreatic cancer due to the tumor's protective physical and immunosuppressive environment.
Hacker News (Newest) files mainly under programming. We currently carry 5,306 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Hacker News (Newest) |
| Canonical URL | https://www.worksinprogress.news/p/pancreatic-cancer-just-met-its-match |
| Publication time | Sat, 16 May 2026 19:29:19 +0000 |
| Retrieval time | 2026-05-16T19:40:19.037Z |
| Last seen | 2026-05-16T19:40:19.037Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | M_tEQ0ixQ0a6 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Pancreatic cancer just met its matchA disease that was once a death sentence is increasingly treatableRuxandra Teslo and Works in ProgressMay 12, 20262151422ShareFor most of the last half-century, a diagnosis of metastatic pancreatic cancer was a death sentence. In December 2025, former Nebraska Senator Ben Sasse announced he had been diagnosed with stage four pancreatic cancer that had spread to his lungs, liver and other organs, and was given three to four months to live from the time of diagnosis. With little to lose, he enrolled in a clinical trial for an experimental drug. Four months later, he reported a 76 percent reduction in tumor volume, describing the drug, daraxonrasib, as a ‘miracle’. His face, ravaged by a severe skin rash from the treatment, told a more complicated story.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Hacker News (Newest).
Discussion
0 commentsMore from Hacker News (Newest)
